References
- Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013;382:209–222.
- Mor S, Tzipori S. Cryptosporidiosis in children in sub-Saharan Africa: a lingering challenge. Clin Infect Dis. 2008;47(7):915–921.
- Shirley D-AT, Moonah SN, Kotloff KL. Burden of disease from cryptosporidiosis. Curr Opin Infect Dis [Internet]. 2012 [cited 2019 Oct 26];25:555–563. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22907279.
- Ahmadpour E, Safarpour H, Xiao L, et al. Cryptosporidiosis in HIV-positive patients and related risk factors: a systematic review and meta-analysis [Internet]. Parasite EDP Sciences; 2020 [cited 2020 Oct 8]. Available from: /pmc/articles/PMC7191976/?report=abstract.
- Amadi B, Mwiya M, Sianongo S, et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect Dis. 2009;9:195.
- Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: A randomised controlled trial. Lancet [Internet]. 2002 [cited 2020 Oct 12];360:1375–1380. Available from: https://pubmed.ncbi.nlm.nih.gov/12423984/.
- Rossignol JFA, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis [Internet]. 2001 [cited 2020 Oct 12];184:103–106. Available from: https://pubmed.ncbi.nlm.nih.gov/11398117/.
- Pilla AM, Rybak MJ, Chandrasekar PH. Spiramycin in the treatment of cryptosporidiosis. Pharmacother J Hum Pharmacol Drug Ther [Internet]. 1987 [cited 2020 Oct 12];7:188–190. Available from: https://pubmed.ncbi.nlm.nih.gov/3432095/.
- Griffiths JK, Balakrishnan R, Widmer G, et al. Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery. Infect Immun [Internet]. 1998 [cited 2020 Oct 12];66:3874–3883. Available from: /pmc/articles/PMC108441/?report=abstract.
- Gathe JC, Mayberry C, Clemmons J, et al. Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS [Internet]. J Acquir Immune Defic Syndr. 2008 [cited 2020 Jun 28]:365–366. Available from: https://pubmed.ncbi.nlm.nih.gov/18580340/.
- Maurya SK, Gollapalli DR, Kirubakaran S, et al. Triazole inhibitors of Cryptosporidium parvum inosine 5’-monophosphate dehydrogenase. J Med Chem [Internet]. 2009 [cited 2019 Oct 19];52:4623–4630. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19624136.
- Kim Y, Makowska-Grzyska M, Gorla SK, et al. Structure of Cryptosporidium IMP dehydrogenase bound to an inhibitor with in vivo antiparasitic activity. Acta Crystallogr Sect FStructural Biol Commun. 2015;71:531–538.
- Gorla SK, Kavitha M, Zhang M, et al. Selective and potent urea inhibitors of cryptosporidium parvum inosine 5′-monophosphate dehydrogenase. J Med Chem. 2012;55:7759–7771.
- Sun Z, Khan J, Makowska-Grzyska M, et al. Synthesis, in vitro evaluation and cocrystal structure of 4-oxo-[1]benzopyrano[4,3-c]pyrazole Cryptosporidium parvum inosine 5’-monophosphate dehydrogenase (CpIMPDH) inhibitors. J Med Chem [Internet]. 2014 [cited 2019 Oct 19];57:10544–10550. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25474504.
- Makowska-Grzyska M, Kim Y, Maltseva N, et al. A novel cofactor-binding mode in bacterial IMP dehydrogenases explains inhibitor selectivity. J Biol Chem. 2015;290:5893–5911.
- Wang W, Hedstrom L. Kinetic mechanism of human inosine 5’-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products. Biochemistry [Internet]. 1997 [cited 2019 Oct 26];36:8479–8483. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9214292.
- Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109:2903–2928.
- Striepen B, Pruijssers AJP, Huang J, et al. Gene transfer in the evolution of parasite nucleotide biosynthesis. Proc Natl Acad Sci U S A. 2004;101:3154–3159.
- Umejiego NN, Li C, Riera T, et al. Cryptosporidium parvum IMP dehydrogenase: identification of functional, structural, and dynamic properties that can be exploited for drug design. J Biol Chem. 2004;279:40320–40327.
- Zhang RG, Evans G, Rotella FJ, et al. Characteristics and crystal structure of bacterial inosine-5’- monophosphate dehydrogenase. Biochemistry. 1999;38:4691–4700.
- Omolabi KF, Agoni C, Olotu FA, et al. Molecular basis of P131 Cryptosporidial-IMPDH selectivity — a structural, dynamical and mechanistic stance. Cell Biochem Biophys [Internet]. 2020; doi:10.1007/s12013-020-00950-1.
- Mushtaq S, Abbasi BH, Uzair B, et al. Natural products as reservoirs of novel therapeutic agents [Internet]. EXCLI J. Leibniz Research Centre for Working Environment and Human Factors; 2018 [cited 2020 Oct 15]. p. 420–451. Available from: /pmc/articles/PMC5962900/?report=abstract.
- Ndjonka D, Ajonina-Ekoti I, Djafsia B, et al. Anogeissus leiocarpus extract on the parasite nematode Onchocerca ochengi and on drug resistant mutant strains of the free-living nematode Caenorhabditis elegans. Vet Parasitol [Internet]. 2012 [cited 2020 Oct 15];190:136–142. Available from: https://pubmed.ncbi.nlm.nih.gov/22727616/.
- Cho-Ngwa F, Abongwa M, Ngemenya MN, et al. Selective activity of extracts of Margaritaria discoidea and Homalium africanum on Onchocerca ochengi. BMC Complement Altern Med [Internet]. 2010 [cited 2020 Oct 15];10. Available from: https://pubmed.ncbi.nlm.nih.gov/21029456/.
- Smith RA, Pontiggia L, Waterman C, et al. Comparison of motility, recovery, and methyl-thiazolyl-tetrazolium reduction assays for use in screening plant products for anthelmintic activity. Parasitol Res [Internet]. 2009 [cited 2020 Oct 15];105:1339–1343. Available from: https://pubmed.ncbi.nlm.nih.gov/19629527/.
- Utzinger J, Shuhua X, N’Goran EK, et al. The potential of artemether for the control of schistosomiasis [Internet]. Int J Parasitol. 2001 [cited 2020 Oct 15]:1549–1562. Available from: https://pubmed.ncbi.nlm.nih.gov/11730781/.
- Xiao SH, Booth M, Tanner M. The prophylactic effects of artemether against schistosoma japonicum infections. Parasitol Today. Elsevier Ltd; 2000:16(3):122–126.
- Magalhães LG, Machado CB, Morais ER, et al. In vitro schistosomicidal activity of curcumin against Schistosoma mansoni adult worms. Parasitol Res [Internet]. 2009 [cited 2020 Oct 15];104:1197–1201. Available from: https://pubmed.ncbi.nlm.nih.gov/19096877/.
- Jisaka M, Kawanaka M, Michael M, et al. Antischistosomal activities of sesquiterpene lactones and steroid glucosides from Vernonia amygdalina, possibly used by wild chimpanzees against parasite-related diseases. Biosci Biotechnol Biochem [Internet]. 1992 [cited 2020 Oct 15];56:845–846. Available from: https://pubmed.ncbi.nlm.nih.gov/1368347/.
- Soliman MFM. Evaluation of avocado/soybean unsaponifiable alone or concurrently with praziquantel in murine schistosomiasis. Acta Trop [Internet]. 2012 [cited 2020 Oct 15];122:261–266. Available from: https://pubmed.ncbi.nlm.nih.gov/22342904/.
- Kato MJ, Furlan M. Chemistry and evolution of the Piperaceae. Pure Appl Chem. 2007;79:529–538.
- Da Silva Filho AA, Costa ES, Cunha WR, et al. In vitro antileishmanial and antimalarial activities of tetrahydrofuran lignans isolated from Nectandra megapotamica (Lauraceae). Phyther Res [Internet]. 2008 [cited 2020 Oct 15];22:1307–1310. Available from: https://pubmed.ncbi.nlm.nih.gov/18688887/.
- Nour AMM, Khalid SA, Kaiser M, et al. The antiprotozoal activity of sixteen asteraceae species native to Sudan and bioactivity-guided isolation of xanthanolides from xanthium brasilicum. Planta Med [Internet]. 2009 [cited 2020 Oct 15];75:1363–1368. Available from: https://pubmed.ncbi.nlm.nih.gov/19431098/.
- Wang Z, Sun H, Shen C, et al. Combined strategies in structure-based virtual screening [Internet]. Phys Chem Chem Phys Royal Society of Chemistry; 2020 [cited 2020 Oct 15]:3149–3159. Available from: https://pubs.rsc.org/en/content/articlehtml/2020/cp/c9cp06303j.
- Lyne PD. Structure-based virtual screening: an overview [Internet]. Drug Discov Today. 2002 [cited 2020 Oct 15]:1047–1055. Available from: https://pubmed.ncbi.nlm.nih.gov/12546894/.
- Waszkowycz B. Towards improving compound selection in structure-based virtual screening [Internet]. Drug Discov Today. 2008 [cited 2020 Oct 15]:219–226. Available from: https://pubmed.ncbi.nlm.nih.gov/18342797/.
- Cavasotto C, Orry W. Ligand docking and structure-based virtual screening in drug discovery. Curr Top Med Chem [Internet]. 2007 [cited 2020 Oct 15];7:1006–1014. Available from: https://pubmed.ncbi.nlm.nih.gov/17508934/.
- Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery: methods and applications [Internet]. Nat Rev Drug Discov. 2004 [cited 2020 Oct 15]:935–949. Available from: https://pubmed.ncbi.nlm.nih.gov/15520816/.
- Bhardwaj VK, Singh R, Sharma J, et al. Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors. J Biomol Struct Dyn [Internet]. 2020 [cited 2021 Feb 15];1–10. Available from: https://www.tandfonline.com/doi/full/10.1080/07391102.2020.1766572.
- Bhardwaj VK, Singh R, Sharma J, et al. Structural based study to identify new potential inhibitors for dual specificity tyrosine-phosphorylation- regulated kinase. Comput Methods Programs Biomed [Internet]. 2020 [cited 2021 Feb 15];194:105494. Available from: https://linkinghub.elsevier.com/retrieve/pii/S016926072030167X.
- Schneider G. Virtual screening: an endless staircase? [Internet]. Nat Rev Drug Discov. 2010 [cited 2020 Oct 15]:273–276. Available from: https://pubmed.ncbi.nlm.nih.gov/20357802/.
- Shoichet BK. Virtual screening of chemical libraries. Nature. 2004;432:862–865.
- Eswar N, Webb B, Marti-Renom MA, et al. Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci. 2007;Chapter 2:Unit 2.9. Available from: https://pubmed.ncbi.nlm.nih.gov/18429317/
- Yang Z, Lasker K, Schneidman-Duhovny D, et al. UCSF Chimera, MODELLER, and IMP: an integrated modeling system. J Struct Biol. 2012;179:269–278.
- Trott O, Olson AJ. Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–461.
- Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera – a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–1612.
- Case DA. Amber 18. Univ California, San Fr. 2018.
- Wang J, Wolf RM, Caldwell JW, et al. Development and testing of a general amber force field. J Comput Chem [Internet]. 2004 [cited 2019 Oct 26];25:1157–1174. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15116359.
- Grest GS, Kremer K. Molecular dynamics simulation for polymers in the presence of a heat bath. Phys Rev A. 1986;33:3628–3631.
- Roe DR, Cheatham TE. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9:3084–3095.
- Seifert E. Originpro 9.1: scientific data analysis and graphing software-software review. J Chem Inf Model [Internet]. 2014 [cited 2019 Oct 26];54:1552. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24702057.
- Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov [Internet]. 2015 [cited 2019 Oct 26];10:449–461. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25835573.
- Ylilauri M, Pentikäinen OT. MMGBSA as a tool to understand the binding affinities of filamin-peptide interactions. J Chem Inf Model. 2013;53:2626–2633.
- Karthick V, Nagasundaram N, Doss CGP, et al. Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus. Infect Dis Poverty. 2016;5:12.
- Lawal M, Olotu FA, Soliman MES. Across the blood-brain barrier: neurotherapeutic screening and characterization of naringenin as a novel CRMP-2 inhibitor in the treatment of Alzheimer’s disease using bioinformatics and computational tools. Comput Biol Med. 2018;98:168–177.
- Liao C, Sitzmann M, Pugliese A, et al. Software and resources for computational medicinal chemistry. Future Med Chem. 2011;3(8): 1057–1085.
- Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:1–13.
- Sander T, Freyss J, Von Korff M, et al. Datawarrior: an open-source program for chemistry aware data visualization and analysis. J Chem Inf Model [Internet]. 2015 [cited 2020 Aug 14];55:460–473. Available from: https://pubs.acs.org/doi/abs/10.1021/ci500588j.
- Molinspiration Cheminformatics [Internet]. [cited 2020 May 1]. Available from: https://www.molinspiration.com/.
- Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44:235–249.
- McConkey B, Sobolev V, Edelman M. The performance of current methods in ligand-protein docking. undefined. 2002.
- Trott O, Olson A. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010;31:455–461.
- Valley CC, Cembran A, Perlmutter JD, et al. The Methionine-aromatic motif plays a unique role in stabilizing protein structure. 2012 [cited 2020 Oct 25]; Available from: http://www.jbc.org/cgi/doi/10.1074/jbc.M112.374504.
- Samanta U, Chakrabarti P. Assessing the role of tryptophan residues in the binding site. Protein Eng [Internet]. 2001 [cited 2020 Oct 26];14:7–15. Available from: https://pubmed.ncbi.nlm.nih.gov/11287674/.
- Macias MJ, Wiesner S, Sudol M. WW and SH3 domains, two different scaffolds to recognize proline-rich ligands [Internet]. FEBS Lett; 2002 [cited 2020 Oct 26]:30–37. Available from: https://pubmed.ncbi.nlm.nih.gov/11911877/.
- Kuzmanic A, Zagrovic B. Determination of ensemble-average pairwise root mean square deviation from experimental B-factors. Biophys J. 2010;98:861–871.
- Brüschweiler R. Efficient RMSD measures for the comparison of two molecular ensembles. Proteins Struct Funct Bioinforma [Internet]. 2002 [cited 2020 Jun 1];50:26–34. Available from: http://doi.wiley.com/10.1002/prot.10250.
- Gunasekaran K, Nussinov R. How different are structurally flexible and rigid binding sites? Sequence and structural features discriminating proteins that do and do not undergo conformational change upon ligand binding. J Mol Biol [Internet]. 2007 [cited 2020 Nov 8];365:257–273. Available from: https://pubmed.ncbi.nlm.nih.gov/17059826/.
- Gutteridge A, Thornton J. Conformational changes observed in enzyme crystal structures upon substrate binding. J Mol Biol [Internet]. 2005 [cited 2020 Nov 8];346:21–28. Available from: https://pubmed.ncbi.nlm.nih.gov/15663924/.
- Hammes-Schiffer S, Benkovic SJ. Relating protein motion to catalysis [Internet]. Annu Rev Biochem. 2006 [cited 2020 Nov 8]:519–541. Available from: https://pubmed.ncbi.nlm.nih.gov/16756501/.
- Lobanov MY, Bogatyreva NS, Galzitskaya OV. Radius of gyration as an indicator of protein structure compactness. Mol Biol. 2008;42:623–628.
- Teilum K, Olsen JG, Kragelund BB. Functional aspects of protein flexibility [Internet]. Cell Mol Life Sci. 2009 [cited 2020 Aug 18];66(14):2231–2247. Available from: https://pubmed.ncbi.nlm.nih.gov/19308324/.
- Murphy KP. Stabilization of protein structure. Methods Mol Biol. 2001;168:1–16.
- Lee B, Richards FM. The interpretation of protein structures: estimation of static accessibility. J Mol Biol [Internet]. 1971 [cited 2020 Nov 12];55. Available from: https://pubmed.ncbi.nlm.nih.gov/5551392/.
- Gromiha M, Ahmad S. Role of solvent accessibility in structure based drug design. Curr Comput Aided-Drug Des [Internet]. 2005 [cited 2020 Aug 18];1:223–235. Available from: http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1573-4099&volume=1&issue=3&spage=223.
- Pace CN, Shirley BA, McNutt M, et al. Forces contributing to the conformational stability of proteins. FASEB J [Internet]. 1996 [cited 2020 Aug 18];10:75–83. Available from: https://pubmed.ncbi.nlm.nih.gov/8566551/.
- Lapidus LJ, Yao S, McGarrity KS, et al. Protein hydrophobic collapse and early folding steps observed in a microfluidic mixer. Biophys J [Internet]. 2007 [cited 2020 Aug 18];93:218–224. Available from: https://pubmed.ncbi.nlm.nih.gov/17416618/.
- Brun L, Isom DG, Velu P, et al. Hydration of the folding transition state ensemble of a protein. Biochemistry [Internet]. 2006 [cited 2020 Aug 18];45:3473–3480. Available from: https://pubmed.ncbi.nlm.nih.gov/16533028/.
- Karplus M, Ichiye T. Comment on a “Fluctuation and cross-correlation analysis of protein motions observed in nanosecond molecular dynamics simulations”. J Mol Biol [Internet]. 1995 [cited 2020 Nov 15];252:492–503. Available from: https://pubmed.ncbi.nlm.nih.gov/7563068/.
- Arnold GE, Ornstein RL. Molecular dynamics study of time-correlated protein domain motions and molecular flexibility: cytochrome P450BM-3. Biophys J. 1997;73:1147–1159.
- David CC, Jacobs DJ. Principal component analysis: a method for determining the essential dynamics of proteins. Methods Mol Biol [Internet]. 2014 [cited 2020 Aug 18];1084:193–226. Available from: /pmc/articles/PMC4676806/?report=abstract.
- Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
- Arnott JA, Planey SL. The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov. 2012;7:863–875.
- Ertl P, Schuffenhauer A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J Cheminform. 2009;1:8.
- Fernandes J, Gattass CR. Topological polar surface area defines substrate transport by multidrug resistance associated protein 1 (MRP1/ABCC1). J Med Chem. 2009;52:1214–1218.
- Hopkins AL, Keserü GM, Leeson PD, et al. The role of ligand efficiency metrics in drug discovery. Nat Rev Drug Discov. 2014;13:105–121.
- Bembenek SD, Tounge BA, Reynolds CH. Ligand efficiency and fragment-based drug discovery. Drug Discov Today. 2009;14(5–6):278–283.
- Nissink JWM. Simple size-independent measure of ligand efficiency. J Chem Inf Model. 2009;49:1617–1622.
- Reynolds CH, Tounge BA, Bembenek SD. Ligand binding efficiency: trends, physical basis, and implications. J Med Chem. 2008;51:2432–2438.